William Blair Investment Management LLC Has $25 Million Holdings in ANI Pharmaceuticals, Inc. $ANIP

William Blair Investment Management LLC cut its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 9.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 316,693 shares of the specialty pharmaceutical company’s stock after selling 31,987 shares during the quarter. William Blair Investment Management LLC’s holdings in ANI Pharmaceuticals were worth $25,000,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Divisadero Street Capital Management LP acquired a new position in ANI Pharmaceuticals in the 3rd quarter worth $21,454,000. Apis Capital Advisors LLC boosted its stake in ANI Pharmaceuticals by 28.1% in the 3rd quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock worth $15,022,000 after purchasing an additional 36,000 shares during the period. Oliver Luxxe Assets LLC acquired a new position in ANI Pharmaceuticals in the 4th quarter worth $1,823,000. Artemis Investment Management LLP acquired a new position in ANI Pharmaceuticals in the 4th quarter worth $1,706,000. Finally, Thrivent Financial for Lutherans boosted its stake in ANI Pharmaceuticals by 363.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 58,027 shares of the specialty pharmaceutical company’s stock worth $5,315,000 after purchasing an additional 45,516 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $82.72 on Tuesday. The company’s 50-day moving average price is $78.10 and its two-hundred day moving average price is $79.93. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. ANI Pharmaceuticals, Inc. has a one year low of $56.71 and a one year high of $99.50. The stock has a market capitalization of $1.88 billion, a PE ratio of 20.94 and a beta of 0.46.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. During the same period in the previous year, the firm posted $1.70 EPS. The company’s revenue for the quarter was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ANIP has been the subject of a number of research analyst reports. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $107.33.

Insider Activity

In other ANI Pharmaceuticals news, Director Patrick D. Walsh sold 10,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total transaction of $806,300.00. Following the sale, the director directly owned 38,432 shares of the company’s stock, valued at $3,098,772.16. The trade was a 20.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Thomas Andrew Rowland sold 459 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $79.21, for a total transaction of $36,357.39. Following the sale, the senior vice president directly owned 38,271 shares in the company, valued at $3,031,445.91. This trade represents a 1.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 91,427 shares of company stock worth $7,089,066. 8.10% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.